题名

非酒精性脂肪肝疾病的診斷與治療

作者

蘇慶豐；陳亮仁

关键词
期刊名称

家庭醫學與基層醫療

卷期/出版年月

30卷9期（2015 / 09 / 25）

页次

255 - 260

内容语文

繁體中文
主题分类 醫藥衛生 > 預防保健與衛生學
醫藥衛生 > 社會醫學
参考文献
  1. 衛生福利部疾病管制署. 台灣統計資料https://www.cdc.gov.tw/professional/knowdisease.aspx?treeid=beac9c103df952c4&nowtreeid=7296679902209942&id=4632 148C425C4923&did=656. Accessed April 2, 2015
  2. 行政院衛生署國民健康局：代謝症候群防治手冊。台北：行政院衛生署國民健康局，2007。
  3. Adams, LA,Lymp, JF,St Sauver, J(2005).The natural history of nonalcoholic fatty liver disease: a population-based cohort study.Gastroenterology,129,113-21.
  4. Ali, AH,Amir, Z,Sonia, O,Homa, M(2012).Effects of Metformin, Pioglitazone, and Silymarin treatment on non-alcoholic fatty liver disease: A randomized controlled pilot study.Hepatitis Monthly,12,e6099.
  5. Angulo, P(2002).Nonalcoholic fatty liver disease.N Engl J Med,346,1221-31.
  6. Angulo, P,Hui, JM,Marchesini, G(2007).The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.Hepatology,45,846-54.
  7. Athyros,VG,Mikhailidis, DP,Didangelos, TP(2006).Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.Curr Med Res Opin,22,873-83.
  8. Bedogni, G,Bellentani, S,Miglioli, L(2006).The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.BMC Gastroenterol,2,6-33.
  9. Boettcher, E,Csako, G,Pucino, F,Wesley, R,Loomba, R(2012).Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.Aliment Pharmacol Ther,35,66-75.
  10. Braunersreuther, V,Viviani, GL,Mach, F(2012).Role of cytokines and chemokines in non-alcoholic fatty liver disease.World J Gastroenterol,18,727-35.
  11. Chalasani, N(2005).Statin hepatotoxicity: focus on statin usage in nonalcoholic fatty liver disease.Hepatol,41,690-95.
  12. Chen, CH,Huang, MH,Yang, JC, J(2006).Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.Clin Gastroenterol,40,745-52.
  13. Cnop, M,Landchild, MJ,Vidal, J(2002).The concurrent accumulation of intraabdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments.Diabetes,51,1005-15.
  14. Donnelly, KL,Smith, CI,Schwarzenberg, SJ,Jessurun, J,Boldt, MD,Parks, EJ(2005).Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.J Clin Invest,115,1343-51.
  15. Dowman, JK,Tomlinson, JW,Newsome, PN(2011).Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis.Aliment Pharmacol Ther,33,525-40.
  16. Du, J,Ma, YY,Yu, CH,Li ,YM(2014).Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis.World J Gastroenterol,20,569-77.
  17. Dyson, JK,Anstee, QM,McPherson, S(2014).Nonalcoholic fatty liver disease: a practical approach to treatment.Frontline Gastroenterol,5,277-86.
  18. Ekstedt, M,Franzen, LE,Mathiesen, UL(2006).Long-term follow-up of patients with NAFLD and elevated liver enzymes.Hepatol,44,865-73.
  19. Fernández-Miranda, C,Pérez-Carreras, M,Colina ,F,López-Alonso, G,Vargas, C,Solís-Herruzo, JA(2008).A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.Dig Liver Dis,40,200-5.
  20. Ferwana, M,Firwana, B,Hasan, R(2013).Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.Diabet Med,30,1026-32.
  21. García-Ruiz, C,Baulies, A,Mari, M,García-Rovés, PM,Fernandez-Checa, JC(2013).Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: cause or consequence?.Free Radic Res,47,854-68.
  22. Guyatt, GH,Oxman, AD,Schünemann, HJ(2011).GRADE guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables.J Clin Epidemiol,64,383-94.
  23. Hallsworth, K,Fattakhova, G,Hollingsworth, KG(2011).Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss.Gut,60,1278-83.
  24. Harrison, SA,Torgerson, Shayashi, P,Ward, J,Schenker, S(2003).Vitamin E and vitamin C treatment improves fibrosis is patients with nonalcoholic steatohepatitis.Am J Gastroenterol,98,2485-90.
  25. Hassan, S,Ramin,G,Amir, M(2014).Silymarin in treatment of non-alcoholic steatohepatitis:a randomized clinical trial.Caspian J Int Med,5,9-12.
  26. Hatzitolios, A,Savopoulos, C,Lazaraki, G(2004).Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia.Indian J Gastroenterol,23,131-4.
  27. Hung, SC,Lai, SW,Chen, MC,Li, PC,Lin, KC(2013).Prevalence and related factors of nonalcoholic fatty liver disease among the elderly in Taiwan.European Geriatric Medicine,4,78-81.
  28. Ilan, Y(2012).Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis.World J Gastroenterol,18,2609-18.
  29. Johnson, NA,Sachinwalla, T,Walton, DW(2009).Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss.Hepatology,50,1105-12.
  30. Kirwan, JP,Solomon, TP,Wojta, DM,Staten, MA,Holloszy, JO(2009).Effects of 7 days of exercise training on insulin sensitivity and responsiveness in type 2 diabetes mellitus.Am J Physiol Endocrinol Metab,297,E151-6.
  31. Klein, EA,Thompson, IM,Tangen, CM(2011).Vitamin E and the risk of prostate cancer. The selenium and vitamin E cancer prevention trial (SELECT).JAMA,306,1549-56.
  32. Kostapanos, MS1,Kei, A,Elisaf, MS(2013).Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease.World J Hepatol,5,470-8.
  33. LaBrecque, DR,Abbas, Z,Anania, F(2014).World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.J Clin Gastroenterol,48,467-73.
  34. Laurin, J,Lindor, KD,Crippin, JS(1996).Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.Hepatology,23,1464-7.
  35. Li, Y,Liu, L,Wang, B,Wang, J,Chen, D(2013).Metformin in non-alcoholic fatty liver disease: a systematic review and metaanalysis.Biomed Rep,1,57-64.
  36. Lindor, KD,Kowldey, KV,Heathcote, EJ(2004).Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.Hepatology,39,770-8.
  37. Ma, YY,Li, L,Hui, C(2013).Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.World J Gastroenterol,19,6911-8.
  38. Marchesinim, G,Brizi, M,Bianchi, G(2001).Metformin in non-alcoholic steatohepatitis.Lancet,358,893-4.
  39. Mili, S,Stimac, D(2012).Nonalcoholic fatty liver disease/steatohepatitis: epidemiology,pathogenesis, clinical presentation and treatment.Dig Dis,30,158-62.
  40. Miller, ER, 3rd,Pastor-Barriuso, R,Dalal, D,Riemersma, RA,Appel, LJ,Guallar, E(2005).Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.Ann Intern Med,142,37-46.
  41. Mohesn, M,Amirmansoor, R,Mohammad, P(2013).Effects of Silymarin on reducing liver aminotransferases in patients with nonalcoholic fatty liver diseases.Iranian J Gastroenterol& Hepatol,18,181.
  42. Naga, C,Zobair, Y,Joel, EL(2012).The Diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.Hepatol,55,2005-23.
  43. Parker, HM,Johnson, NA,Burdon, CA,Cohn, JS,O'Connor, HT,George, J(2012).Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and metaanalysis.J Hepatol,56,944-51.
  44. Pascale, A,Pais, R,Ratziu, V(2010).An overview of nonalcoholic steatohepatitis: past, present and future directions.J Gastrointestin Liver Dis,19,415-23.
  45. Pastori, D,Polimeni, L,Baratta, F,Pani, A,Del Ben, M,Angelico, F(2015).The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease.Dig Liver Dis,47,4-11.
  46. Promrat, K,Kleiner, DE,Niemeier, HM(2010).Randomized controlled trial testing the effects of weight loss on Nonalcoholic Steatohepatitis.Hepatology,51,121-9.
  47. Saikusa, M,Yatsuga, S,Tonan, T,Koga, Y(2013).Glycogenic hepatopathy and non-alcoholic fatty liver disease in type 1 diabetes patients.Pediatr Int,55,806-7.
  48. Sanyal, AJ,Brunt, EM,Kleiner, DE(2011).Endpoints and clinical trial design for nonalcoholic steatohepatitis.Hepatology,54,344-53.
  49. Sanyal, AJ,Chalasani, N,Kowdley, KV(2010).Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.N Engl J Med,363,1185-6.
  50. Sanyal, AJ,Mofrad, PS,Contos, MJ(2004).A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol,2,1107-15.
  51. Sombat, T,Einar, B,Felicity, E(2013).NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.World J Gastroenterol,19,1219-29.
  52. Strieter, RM,Remick, DG,Ward, PA(1988).Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline.Biochem Biophys Res Commun,155,1230-6.
  53. Tailleux, A,Wouters, K,Staels, B(2012).Roles of PPARs in NAFLD: potential therapeutic targets.Biochim Biophys Acta,1821,809-19.
  54. Targher, G,Bertolini, L,Padovani, R(2010).Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes.J Hepatol,53,713-8.
  55. Targher, G1,Day, CP,Bonora, E(2010).Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.N Engl J Med,363,1341-50.
  56. Thoma, C1,Day, CP,Trenell, MI(2012).Lifestyle interventions for the treatment of nonalcoholic fatty liver disease in adults: a systematic review.J Hepatol,56,225-66.
  57. Tsai, CH1,Li, TC,Lin, CC(2008).Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease.South Med J,101,900-5.
  58. Tung, TH,Chang, TH,Chiu, WH(2011).Clinical correlation of nonalcoholic fatty liver disease in a Chinese taxi drivers population in Taiwan: experience at a teaching hospital.BMC Res Notes,4,315.
  59. UK Prospective Diabetes Study (UKPDS) Group(1988).Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).Lancet,352,854-65.
  60. Uygun, A,Kadayifci, A,Isik, AT(2004).Metformin in the treatment of patients with non-alcoholic steatohepatitis.Aliment Pharmacol Ther,19,537-44.
  61. Vernon, G,Baranova, A,Younossi, ZM(2011).Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.Aliment Pharmacol Ther,34,274-85.
  62. Vuppalanchi, R,Gould, RJ,Wilson, LA(2011).Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.Hepatol Int,6,379-85.
  63. Vuppalanchi, R,Teal, E,Chalasani, N(2005).Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.Am J Med Sci,329,62-5.
  64. Wieckowska, A,McCullough, AJ,Feldstein, AE(2007).Noninvasis diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.Hepatology,46,582-9.
  65. Wieckowska, A,Zein, NN,Yerian, LM,Lopez, AR,McCullough,AJ,Feldstein, AE(2006).In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.Hepatology,44,27-33.
  66. Xiang, Z,Chen, YP,Ma, KF(2013).The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review.BMC Gastroenterol,13,140.
  67. Yakaryilmaz, F,Guliter, S,Savas, B(2007).Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis, results of a pilot study.Intern Med J,37,229-35.
  68. Yoon, HJ,Cha, BS(2014).Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease.World J Hepatology,6,800-11.
  69. Zeng, T,Zhang, CL,Zhao, XL,Xie, KQ(2014).Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a metaanalysis of randomized double-blind, placebocontrolled studies.Eur J Gastroenterol Hepatol,26,646-53.
被引用次数
  1. 周元浚(2018)。陰電性低密度脂蛋白對巨噬細胞極化的影響：LOX-1 扮演的關鍵角色。臺灣大學生物化學暨分子生物學研究所學位論文。2018。1-90。 
  2. 屠智宏(2016)。B28號藥水層萃取物改善倉鼠因高油高膽固醇飲食引起之非酒精性脂肪肝炎。臺灣大學生物化學暨分子生物學研究所學位論文。2016。1-90。 
print cancel